Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase-II Randomized Clinical Trial to Evaluate the Effect of Pirfenidone Compared to Placebo in Post-COVID19 Pulmonary Fibrosis

NCT04607928 is registered in ClinicalTrials.gov with Institut d'Investigació Biomèdica de Bellvitge as lead sponsor.

NCT NCT04607928
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04607928 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase-II Randomized Clinical Trial to Evaluate the Effect of Pirfenidone Compared to Placebo in Post-COVID19 Pulmonary Fibrosis
Lead sponsor
Institut d'Investigació Biomèdica de Bellvitge
Phase
Phase 2
Overall status
Unknown status
Start date
August 1, 2020
Completion date
June 30, 2022
Enrollment
148 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

fibrotic pulmonary sequelae post-covid19 infection